Tehran University of Medical Sciences Iranian Journal of Allergy, Asthma and Immunology 1735-1502 17 3 2018 06 10 240 249 EN Majid Asadi-Ghalehni Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran Mohamad Javad Rasaee Department of Medical Biotechnology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran Nabiollah Namvar Asl Laboratory of Animal Sciences, Pasteur Institute of Iran, Tehran, Iran Masood Khosravani Department of Nanomedicine, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran Masoumeh Rajabibazl Department of Clinical Biochemistry, Shahid Beheshti University of Medical Sciences, Tehran, Iran Saeed khalili Department of Medical Biotechnology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran AND Department of Biology Sciences, Shahid Rajaee Teacher Training University, Tehran, Iran Helmout Modjtahedi Department of Life Sciences, Faculty of Science, Engineering and Computing, Kingston University, London, England Esmaeil Sadroddiny Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran 2017 06 16 2017 12 26 Over expression of the epidermal growth factor receptor (EGFR) in many human epithelial tumors has been correlated with disease progression and poor prognosis. EGFR-inhibiting immunotherapy has already been introduced in cancer therapy. Peptide displaying phage particles in eukaryotic hosts can behave as antigen carriers, able to activate the innate immune system and to elicit adaptive immunity. Herein, the M13-pAK8-VIII phagemid plasmid was engineered to contain the sequences for an EGFR mimotope along with the L2 extracellular domain of EGFR (EM-L2) which would produce the final peptide-phage vaccine. The prophylactic and therapeutic effects of this novel vaccine were evaluated on the Lewis lung carcinoma induced mouse (C57/BL6) model. The recombinant peptide was confirmed to be displayed on the surface of M13 phage as an extension for phage’s PVIII protein. Immunization of mice with peptide-phage vaccine resulted in antibody production against EM-L2 and significant reduction of tumor growth rate by nearly 25 percent. In conclusion, EM-L2 displaying phage particles could be deemed as an encouraging strategy in contemporary cancer immunotherapy. https://ijaai.tums.ac.ir/index.php/ijaai/article/view/1516 https://ijaai.tums.ac.ir/index.php/ijaai/article/download/1516/830